IGS1.F India Globalization Capital Inc

Healthcare Biotechnology Frankfurt Exchange
0.1790 EUR
Close of Nov 12, 2026
0.1630 0.3260
Market cap
EUR 20.9M
P/E
-
P/B
3.68x
ROE
-107.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Mar 2026.

Is IGS1.F undervalued?

Graham number

The Graham number of India Globalization Capital Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

India Globalization Capital Inc fundamental analysis

No fundamental analysis for India Globalization Capital Inc yet.

India Globalization Capital Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About India Globalization Capital Inc

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, th…

Full company profile